Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CHM-1101 |
| Synonyms | |
| Therapy Description |
CHM-1101 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing a CD28 costimulatory domain and CD3zeta domain linked to chlorotoxin (CLTX), which targets MMP2 on tumor cells, and potentially induces cytotoxicity (J Clin Oncol 41, 2023 (suppl 16; abstr TPS2086, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CHM-1101 | CHM 1101|CHM1101 | CHM-1101 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing a CD28 costimulatory domain and CD3zeta domain linked to chlorotoxin (CLTX), which targets MMP2 on tumor cells, and potentially induces cytotoxicity (J Clin Oncol 41, 2023 (suppl 16; abstr TPS2086, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05627323 | Phase I | CHM-1101 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Active, not recruiting | USA | 0 |